Pediatric Rheumatology

Table 1 J10 and J27-related disease criteria on all patients

From: Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data

%	Disease State*	Baseline N=178	D15 N=172	D29 N=157	D57 N=131	D85 N=125
J10	ID	0.0	18.0	26.8	34.4	33.6
	LDA	0.0	14.0	11.5	16.8	24.8
	MDA	0.6	19.2	19.7	20.6	16.8
	HDA	99.4	48.8	42.0	28.2	24.8
J27	ID	0.0	18.0	26.8	34.4	33.6
	LDA	0.0	14.0	11.5	16.8	25.6
	MDA	0.6	15.1	16.6	17.6	12.8
	HDA	99.4	52.9	45.2	31.3	28.0

*Cut-off values for ID, LDA, MDA and HDA, respectively for J10: ≤1, >1-≤3.8, >3.8 - ≤10.5, >10.5; and for J27: ≤1, >1 - ≤3.8, >3.8 - ≤8.5, >8.5

Back to article page

ISSN: 1546-0096

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com